IVIG for hematologic malignancy-associated secondary immunosuppression may be an option when patients have severe or recurrent infections. Discover how IVIG is administered and find answers to the most common questions. 

Highlights

1. Hematologic malignancy-associated secondary immunosuppression means a weakened immune system caused by hematologic malignancies or their treatments. 
2. IVIG is widely used to prevent recurrent and severe infections in patients with hematologic malignancies. 
3. A patient may switch from IVIG to SCIG in certain situations. 

What Is Hematologic Malignancy-Associated Secondary Immunosuppression?

Let’s first break down the term “hematologic malignancy-associated secondary immunosuppression.” 

Hematologic Malignancy

These cancers originate in the bone marrow or the cells of the immune system. The three main groups of hematologic malignancy are:

1. Leukemia: Leukemia occurs when the bone marrow produces abnormally high amounts of white blood cells. 
2. Lymphoma: Lymphoma originates in the part of the immune system called the lymphatic system. Lymphoma affects white blood cells known as lymphocytes. 
3. Multiple myeloma: This is a rare cancer that causes an overgrowth of specialized white blood cells called plasma cells. 

Secondary Immunosuppression

Secondary immunosuppression refers to a weakened immune system due to:

• Disorders of blood or bone marrow
• Medications
• Cancer treatments
• Certain cancers
• Malnutrition 
• Infectious diseases

Hematologic malignancy-associated secondary immunosuppression occurs when hematologic malignancies or their treatments cause a weakened immune system. A weakened immune system puts patients at a higher risk of getting recurrent or severe infections. 

IVIG (intravenous immunoglobulin) is one of the treatment options for hematologic malignancy-associated immunosuppression. Other management options include:

• Preventive antibiotic treatment and vaccination
• Reduced immunosuppression
• Treatment of the underlying condition

IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: What We Know So Far

IVIG is widely used to help reduce the risk of severe infections in patients with hematologic malignancies. In these patients, IVIG can prevent recurrent and severe infections [1]. A healthcare provider may consider IVIG for hematologic malignancy-associated secondary immunosuppression when [2,3]:

• Patients have severe or recurrent infections
• Antibiotics are ineffective
• IgG level is less than 4g/l
• Patient is receiving CAR-T Cell therapy

Further Reading: IVIG for CAR-T Therapy-Related Hypogammaglobulinemia: Uses, Benefits, Dosage, and More

However, the use of IVIG for hematologic malignancy-associated secondary immunosuppression is still not clear because:

• The benefits of IVIG for hematologic malignancy-associated secondary immunosuppression come from small clinical trials; robust evidence from large controlled trials is lacking. 
• There are no specific clinical treatment guidelines on the use of IVIG in this patient population.

Due to cost and limited supply of IVIG, it is typically recommended for therapy to be individualized based on the patient’s condition and type of cancer therapy. 

Treatment Considerations and Dosing

Administering IVIG for hematologic malignancy-associated secondary immunosuppression involves several steps. 

First, a healthcare provider will measure the IgG levels before or during cancer treatment. Second, they will determine when to start IVIG therapy, which typically relies on the IgG levels. Lastly, they will determine the dose based on the body weight. 

Step 1: Measuring IgG Levels

According to the European expert consensus, in patients with hematologic malignancies [4]:

• Measuring IgG levels before starting cancer treatment can help estimate the patient’s risk of developing infections. 
• A healthcare provider may also measure Ig levels during routine visits if the patient has already started cancer treatment. 

For patients younger than 21 years, a healthcare provider will interpret the IgG levels based on what’s considered normal for their specific age. 

Step 2: Starting IVIG Therapy

The ideal candidates for IVIG for hematologic malignancy-associated secondary immunosuppression are those with:

• IgG levels less than 4 g/l who have received antimicrobial therapy. IVIG should be started during or after a single severe infection or recurrent infection. 
• IgG levels less than 4 g/l who have severe or recurrent infections even after they have received antimicrobial therapy. 

While not all experts agree, patients with IgG levels between 4 g/l and 6 g/l who have severe or recurrent infections even after they have received antimicrobial therapy may also receive IVIG treatment. 

Step 3: IVIG Dosing

IVIG dose depends on body weight. If the patient is obese, dosage adjustment according to the ideal body weight specific to the patient is necessary.

The dosing regimen of IVIG for hematologic malignancy-associated secondary immunosuppression is as follows [3]:

• The starting dose of IVIG is 0.4 g/kg body weight every 3 to 4 weeks. 
• The maintenance dose of IVIG is 0.4 to 0.8 g/kg body weight every 3 to 4 weeks. 

IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Special Considerations

• When starting IVIG therapy, a healthcare provider may consider stopping antimicrobial treatment if the infection is under control. 
• If the patient doesn’t have an infection for a significant period of time (typically 6 months), a healthcare provider may stop IVIG therapy. 
• Patients who no longer use IVIG should get their IgG levels tested during routine visits. 
• Should severe or persistent infections recur in patients who no longer use IVIG, IVIG treatment can be restarted. 
• IVIG typically causes mild infusion-related reactions, such as headache, nausea, and muscle aches. 
• Rare but severe side effects include severe allergic reactions, kidney failure, and rupture of red blood cells. A healthcare provider will closely monitor patients during IVIG therapy if they have risk factors for these serious side effects.

IVIG for Hematologic Malignancy-Associated Secondary Immunosuppression: Can A Patient Switch to Subcutaneous Immune Globulin (SCIG)? 

A patient can switch to SCIG after discussing the potential benefits and risks with their healthcare provider. The major benefit is that they can self-administer SCIG at home after proper training. SCIG typically also has fewer side effects than IVIG. They may choose to switch to SCIG if:

• They are ready to take charge of their health.
• Other forms of treatment fail to provide adequate IgG levels.
• Specific immunoglobulin formulations are unavailable.

Frequently Asked Questions

What hematologic malignancy is associated with secondary immunosuppression?

Chronic lymphocytic leukemia and multiple myeloma are often associated with secondary immunosuppression. 

Which type of virus has been associated with hematologic malignancies?

Viruses associated with hematologic malignancies include HIV, Epstein–Barr virus (EBV), and Kaposi sarcoma–associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8).

What is the most common cause of secondary immunodeficiency?

The most common causes of secondary immunodeficiency are:

• Blood or bone marrow disorders
• Cancer treatments
• Certain cancers

After major surgical procedures like organ transplantation or open-heart surgery, your body goes through a lot more than what you see on the outside. The physical stress of the procedures can weaken your immune system, which is also known as major surgery-associated secondary immunosuppression or surgery-induced secondary immunosuppression. 

Secondary immunosuppression after major surgery also raises the risks of serious complications like pneumonia, bloodstream infection (sepsis), or delayed wound healing in many patients. Intravenous immunoglobulin (IVIG) is sometimes used as an adjunct therapy to support the immune system during this vulnerable period. 

Read on to learn what surgery-related immunosuppression is, what recent studies show, how IVIG may help, and who may benefit from this treatment.

Major Surgery-Associated Secondary Immunosuppression: Overview

Major surgery-associated secondary immunosuppression occurs as a consequence of an external factor (such as surgery and the physical stress it creates), not by a disease or primary immune defect that the patient may already have. 

Generally, when a person undergoes major surgery such as heart surgery, organ surgery, trauma repair, or a major abdominal operation, their body experiences drastic immunological changes. 

The immune system reacts in two stages: the hyperinflammation phase and the compensatory anti-inflammatory phase (CARS). 

In the hyperinflammation phase, which begins within a few hours after surgery, the body activates a strong inflammatory response to manage the tissue injury. Levels of inflammatory molecules (such as TNF-α, IL-1β, and IL-6) rise, immune cells rush to the injury site, and swelling occurs as part of the healing process. 

After this initial surge, the body shifts into the CARS phase to calm the inflammation caused by elevated cytokines and heightened immune activity. However, sometimes, this “calming response” becomes so strong that it results in immunosuppression. This leads to:

• Reduced immune cell activity (e.g., T cells, B cells & natural killer cells) 
• Reduced antibody levels (IgG and IgM)
• Imbalanced protective cytokine levels
• Impaired neutrophil and macrophage function

These changes typically last from several days to several weeks, depending on the surgery type and patient condition.

Clinical Consequences of Surgery-Induced Immunosuppression

Many post-operative patients, especially those who are older and critically ill, become vulnerable to serious complications due to low immune strength (secondary immunosuppression). Some of the reported clinical complications include: 

• Hypogammaglobulinemia (low level of circulating antibodies)
• Post-operative infections (such as pneumonia, wound infection, sepsis, or septic shock)
• Severe systemic inflammatory response syndrome (SIRS)
• Slower recovery and longer ICU or hospital stays

For instance, a study found that infants who underwent heart surgery with cardiopulmonary bypass experienced a sharp drop in their IgG levels (reduced to less than half of baseline within 24 hours). More than half of the children (about 53%) developed post-operative hypogammaglobulinemia (low IgG). This shows how significantly surgery can weaken their immune defenses.

Similarly, a prospective study of 60 patients undergoing abdominal surgery found that patients who had emergency surgery developed systemic inflammatory response syndrome (SIRS) after the surgery. The higher SIRS scores were associated with a slower recovery process and longer hospital stays. 

IVIG and Secondary Immunosuppression After Surgery: What Research Says

There is currently no strong, high-quality data that directly examines the use of IVIG for major surgery-associated secondary immunosuppression. However, several related studies have reported the promising effects of IVIG in managing post-operative complications that may be caused by secondary immunosuppression.  

For instance, a single-center, prospective, double-blind, randomized study reported that when an intravenous immunoglobulin A- and immunoglobulin M-enriched solution was administered immediately after cardiac surgery, it significantly reduced the incidence of post-operative infections in patients.

Similarly, an ICU-based retrospective study found that IVIG use in ICU septic patients significantly reduced in-hospital mortality and improved laboratory biomarkers (e.g., CRP, albumin) over time. 

Also, a recent systematic review and meta-analysis showed that IVIG, particularly IgM-enriched IVIG, is effective in both adult and neonatal sepsis and reduces sepsis mortality. 

These findings collectively indicate that IVIG may help mitigate post-surgical complications that may be induced by immunosuppression. However, more clinical studies and in-depth trials are required to evaluate the benefits of IVIG in secondary immunosuppression after surgery. 

Understanding the Role of IVIG in Surgery-Induced Immunosuppression

As already mentioned above, IVIG shows promise in selected post-operative situations, especially when a patient has severe infection (sepsis/septic shock) due to immunosuppression. Here are several ways in which IVIG can help reduce surgery-induced immunosuppression. 

1. Restores Antibody Levels and Clears Pathogens

It has been found that patients with complex procedures like heart surgery with cardiopulmonary bypass often develop hypogammaglobulinemia (a sharp drop in IgG/IgM levels due to blood loss, catabolism, or capillary leakage). 

Since IVIG is essentially a concentrated pool of antibodies from thousands of donors, administering IVIG can restore antibody levels. These antibodies then fight pathogens that might cause post-operative secondary infections.

2. Modulates Immune Cell Function

Major surgery impairs immune cells, including T cells, B cells, and monocytes, and reduces their ability to respond to infections. IVIG contains antibodies that interact with immune cells to enhance their function:

• Boosting phagocytosis (how immune cells “eat” bacteria)
• Supporting T-cell responses
• Regulating inflammatory pathways

3. Reduces Risk of Post-operative Infections

By restoring antibodies and supporting immune cell function, IVIG may reduce susceptibility to common post-operative infections, such as pneumonia, surgical site infections, or bloodstream infections.

For instance, a retrospective study of adult patients undergoing orthotopic liver transplantation (OLT) who received an IVIG enriched in IgM (rather than a standard IgG-only formulation) had a significantly lower rate of new bacterial or fungal infections in the first 30 days after transplant and better 90-day survival. 

Some studies suggest that patients receiving IVIG show faster normalization of inflammatory markers, indicating improved immune response, even though evidence is limited.

4. Has Potential Anti-Inflammatory Effects

Surgery triggers a two-phase immune response: hyperinflammation (immediately after surgery) followed by immunosuppression. This sudden drop in immune strength also increases the risk of infection. 

IVIG, which has anti-inflammatory properties, can help balance the immune response, prevent excessive inflammation, and support defense against pathogens.

Even though IVIG has these theoretical benefits, current clinical evidence is limited. IVIG is usually reserved for high-risk patients, especially those with documented antibody deficiency, transplant recipients, and patients with severe infections or sepsis risk post-surgery. 

Who Might Be Considered for IVIG?

IVIG is not routinely used for all surgical patients. Instead, it is generally reserved for selected high-risk individuals based on their clinical status, lab findings, and infection risk. Patients who may be considered include:

• Solid organ or heart/lung/liver transplant recipients with hypogammaglobulinemia or recurrent/severe infections
• Post-operative patients with documented low immunoglobulin levels (e.g., low IgG) and a high risk of serious infection
• Critically ill patients with sepsis or septic shock in whom immune dysfunction or low antibody levels are suspected
• Infants or other vulnerable patients after complex procedures (such as cardiac surgery with cardiopulmonary bypass) who develop significant antibody loss

The decision to use IVIG is always individualized and made by the treating specialist team, taking into account potential benefits, risks, and alternative therapies.

Risks, Limitations, and Cost

Like any blood-derived product, IVIG carries potential risks and is not appropriate for everyone. Possible side effects include infusion reactions (such as headache, fever, or chills), fluid overload, and, more rarely, serious complications like kidney injury or blood clots in patients who are already at risk.

In addition, the current evidence for IVIG use specifically in surgery-associated secondary immunosuppression is limited and based largely on small or heterogeneous studies, so clear treatment guidelines are still evolving. IVIG is also an expensive therapy and may not be covered or approved for all indications, which means its use is typically reserved for patients in whom the expected benefit justifies the cost and potential risks.

The Bottom Line

Major surgeries can temporarily weaken the immune system, leading to secondary immunosuppression, which increases the risk of infections and delays recovery. IVIG may help boost immunity, but data on its use specifically for surgery-associated secondary immunosuppression are limited. 

Few studies, however, suggest a potential role of IVIG in post-operative complications and indicate that it may be considered in high-risk patients, such as transplant recipients or those with antibody deficiencies or septic shock.